CheckMate 214: Post-Hoc Analysis of KIM-1 as a Prognostic Biomarker in aRCC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Wenxin (Vincent) Xu, MD, of Dana-Farber Cancer Institute, and Daniel Joyce, MD, of Vanderbilt University Medical Center, break down the evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma.

The post-hoc analysis of CheckMate 214 provides a crucial take-home message for clinicians regarding KIM-1 testing and implications.